Characteristics of patients with moderate-to-severe ulcerative colitis treated with vedolizumab: results from a Polish multicenter, prospective, observational real-life study (the POLONEZ study)

BACKGROUND: Vedolizumab, a humanized antibody targeting the α(4)β(7) integrin, was proven to be effective in the treatment of moderate-to-severe ulcerative colitis (UC) in randomized clinical trials. The aim of the POLONEZ study is to determine the demographic and clinical characteristics of the pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Cichoż-Lach, Halina, Michalak, Agata, Kopertowska-Majchrzak, Maria, Eder, Piotr, Stawczyk-Eder, Kamila, Waszak, Katarzyna, Talar-Wojnarowska, Renata, Zatorski, Hubert, Solarska-Półchłopek, Anna, Chmielnicki, Jarosław, Filip, Rafał, Pękala, Anna, Janiak, Maria, Skrobot, Krzysztof, Kasińska, Ewa, Krogulecki, Michał, Królikowski, Piotr, Kłopocka, Maria, Liebert, Ariel, Poniewierka, Elżbieta, Smoła, Izabela, Gąsiorowska, Anita, Kaczka, Aleksandra, Wypych, Joanna, Wojciechowski, Krzysztof, Drygała, Szymon, Zagórowicz, Edyta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411627/
https://www.ncbi.nlm.nih.gov/pubmed/34484422
http://dx.doi.org/10.1177/17562848211036456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411627/
https://www.ncbi.nlm.nih.gov/pubmed/34484422
http://dx.doi.org/10.1177/17562848211036456

Ejemplares similares